Steve Porter, MD, MBA
Chief Executive Officer
Dr. Steve Porter, OB/GYN, is passionate about bettering clinical outcomes on a global basis. His residency was under the tutelage of Dr, Nancy Cossler at University Hospitals, and he operationalized that knowledge by refining and iterating the riskLD platform as a one day-per-week hospitalist at UH since inception. Dr. Porter holds a BA, summa cum laude, from Princeton (recipient of the Moses Taylor Pyne Honor Prize), MBA from Harvard Business School, MD with honors from Harvard Medical School and helped launch Zikani Therapeutics during his Blavatnik Fellow in Life Sciences Entrepreneurship at HBS.
Susan Mann, MD, FACOG
Chief Medical Officer
Dr. Susan Mann, FACOG, has been practicing at the Beth Israel Deaconness Medical Center, an affiliate of Harvard Medical School, for the past 30 years. She is Director of Team Training for the OBGYN Department. Dr. Mann is a researcher in Quality Improvement and Measurement in OBGYN, Multi-disciplinary Teamwork, and Healthcare System Engineering. Dr. Mann is the founder of the QualBridge Institute and has engaged with over 100 hospitals in improving workflow and strengthening team communication. She graduated from University of Missouri-Kansas City 6 year BA/MD program.
Steve Mattlin, MS
Chief Technology Officer
Steven was CIO of IntellisEPM, a Cleveland Clinic spin-out which commercialized clinical and operational analytic products including dashboards that allowed intuitive decisions to be made by hospital management to better outcomes. Previously, at DataVantage, as VP of Research, Steven propagated the Exception Based Reporting Data Mining product to numerous MSSQL, Oracle and DB2 customers utilizing various system interfaces. Steven earned a BS in Microbiology from The Ohio State University and a MS in Computer Science specializing in Artificial Intelligence from the University of Iowa.
Rajesh (RK) Khosla, MBA
Founder, Strategy and Finance
RK was previously Chief Business Officer at Black Beret Life Sciences and prior to that, he was founding CEO of Laguna Pharmaceuticals and led it from inception through a $30M Series B. RK learned the funding side as an investing Principal at Crystal Ventures. His expertise is developing scalable business models and assembling teams to execute them. He earned a BS EE/Applied Physics, summa cum laude, with a minor in Economics from Case Western Reserve University. In addition, he has an MBA from Yale University with Letters of Distinction provided in Financial Accounting and Managerial Accounting.
Daniel L Kellogg, MBA
Dan co-founded Crystal Ventures, a $170 million global venture fund focused on high tech investments primarily in software, online content, infrastructure technologies, and semiconductors. Investments were primarily in the U.S. and mainland China. Crystal Ventures invested in 34 companies and took 9 of these companies public. Dan has a BS ChemE from the University of Cincinnati and an MBA from Stanford University.